Technology | April 08, 2008

Mediware Medication Management Software Features Safety Upgrades

The newest version of Mediware's medication management software suite reportedly offers enhanced data integration and functional improvements for tracking of medication orders, administrations and histories.

Version 3.0 is said to provide functional improvements to each application in order to streamline communication between clinicians throughout the hospital. It also includes integration points designed to ease collaboration with other systems within the client�s environment.

Specific product enhancements for the suite include updated safe medication practices information to meet JCAHO inpatient safety standards, improved medication profiles and clinical information, increased alerts and notifications and upgraded screens and displays.

Mediware's suite combines the company's MediREC, WORx, MediMA and MediCOE applications. MediREC includes automated medication reconciliation that electronically captures home medications and provides longitudinal medication records to support reconciliation throughout a patient's stay. WORx is a pharmacy management solution for inpatient and outpatient settings, including inventory management, online adjudication and Web-based access for remote users. MediMAR includes bedside administration and documentation tools designed to ensure the correct medications are delivered to the right patient at the right time. MediCOE�s electronic clinician ordering streamlines orders associated with poor handwriting or patient misidentification.

April 2003

Related Content

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Overlay Init